Poloxamer 188 (P188) as a membrane resealing reagent in biomedical applications

Recent Patents on Biotechnology

Volumn 6, Issue 3, 2012, Pages 200-211

  Moloughney, Joseph G ^c   Weisleder, Noah ^a,b,c,d  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d TRIM edicine Inc   (United States)

Author keywords

Cell transplants; Congestive heart failure; Electrocution; FLOCOR; Free radical injury; Membrane repair; Membrane tension; Muscular dystrophy; Neurodegeneration; Patents; Perfusion therapy; Pluronic; Poloxamer; RheothRx; Surface copolymer; Triblock copolymer

Indexed keywords

BIOCHEMISTRY; BLOCK COPOLYMERS; CARDIOLOGY; CELL DEATH; FREE RADICALS; MEDICAL APPLICATIONS; NEURODEGENERATIVE DISEASES; REPAIR; STABILITY;

CELL TRANSPLANTS; CONGESTIVE HEART FAILURES; ELECTROCUTION; FLOCOR; FREE RADICAL INJURY; MEMBRANE REPAIR; MEMBRANE TENSION; MUSCULAR DYSTROPHY; NEURODEGENERATION; PATENT; PERFUSION THERAPY; PLURONICS; POLOXAMER; RHEOTHRX; SURFACE COPOLYMER; TRIBLOCK-COPOLYMERS;

CELL MEMBRANES;

ACETYLCYSTEINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COPOLYMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG CARRIER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROGOL; POLOXAMER; POLYSORBATE 80; REACTIVE OXYGEN METABOLITE; STREPTOMYCIN;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BECKER MUSCULAR DYSTROPHY; BIODEGRADABILITY; BURN; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL MEMBRANE; CELL REGENERATION; CELL TRANSPLANTATION; CONGESTIVE HEART FAILURE; DIABETIC RETINOPATHY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; ELECTRIC INJURY; HEART FAILURE; HEART PROTECTION; HUMAN; MEDICAL TECHNOLOGY; MEMBRANE DAMAGE; MUSCLE INJURY; MUSCLE REGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATENT; PRIORITY JOURNAL; REPERFUSION INJURY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TISSUE REPAIR; VISUAL IMPAIRMENT;

EID: 84872555746     PISSN: 18722083     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872208311206030200     Document Type: Review

References (93)

1. McNeil PL, Miyake K, Vogel SS. The endomembrane requirement for cell surface repair. Proc Natl Acad Sci U S A. 2003; 100(8):4592-7.
2. McNeil PL, Ito S. Gastrointestinal cell plasma membrane wounding and resealing in vivo. Gastroenterology. 1989;96(5 Pt 1):1238-48.
3. Togo T, Krasieva TB, Steinhardt RA. A decrease in membrane tension precedes successful cell-membrane repair. Mol Biol Cell. 2000;11(12):4339-46.
4. Steinhardt RA. The mechanisms of cell membrane repair: A tutorial guide to key experiments. Ann N Y Acad Sci. 2005;1066:152-65.
5. McNeil PL, Steinhardt RA. Plasma membrane disruption: repair, prevention, adaptation. Annu Rev Cell Dev Biol. 2003;19:697-731.
6. Miyake K, McNeil PL. Vesicle accumulation and exocytosis at sites of plasma membrane disruption. J Cell Biol. 1995;131(6 Pt 2): 1737-45.
7. Steinhardt RA, Bi G, Alderton JM. Cell membrane resealing by a vesicular mechanism similar to neurotransmitter release. Science. 1994;263(5145):390-3.
8. Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423(6936):168-72. Epub 2003/05/09.
9. Bansal D, Campbell KP. Dysferlin and the plasma membrane repair in muscular dystrophy. Trends in cell biology. 2004;14(4):206-13. Epub 2004/04/07.
10. Waddell LB, Lemckert FA, Zheng XF, Tran J, Evesson FJ, Hawkes JM, et al. Dysferlin, annexin A1, and mitsugumin 53 are upregulated in muscular dystrophy and localize to longitudinal tubules of the T-system with stretch. Journal of neuropathology and experimental neurology. 2011;70(4):302-13. Epub 2011/03/18.
11. Evesson FJ, Peat RA, Lek A, Brilot F, Lo HP, Dale RC, et al. Reduced plasma membrane expression of dysferlin mutants is attributed to accelerated endocytosis via a syntaxin-4-associated pathway. The Journal of biological chemistry. 2010;285(37):28529-39. Epub 2010/07/03.
12. Cao CM, Zhang Y, Weisleder N, Ferrante C, Wang X, Lv F, et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation. 2010;121(23):2565-74. Epub 2010/06/03.
13. Wang X, Xie W, Zhang Y, Lin P, Han L, Han P, et al. Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circulation research. 2010;107(1):76-83. Epub 2010/05/15.
14. Weisleder N, Takeshima H, Ma J. Mitsugumin 53 (MG53) facilitates vesicle trafficking in striated muscle to contribute to cell membrane repair. Communicative & integrative biology. 2009;2(3): 225-6. Epub 2009/07/31.
15. Cai C, Weisleder N, Ko JK, Komazaki S, Sunada Y, Nishi M, et al. Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. The Journal of biological chemistry. 2009;284(23):15894-902. Epub 2009/04/22.
16. Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, et al. MG53 nucleates assembly of cell membrane repair machinery. Nature cell biology. 2009;11(1):56-64. Epub 2008/12/02.
17. Doherty KR, McNally EM. Repairing the tears: dysferlin in muscle membrane repair. Trends Mol Med. 2003;9(8):327-30.
18. Bazan NG, Marcheselli VL, Cole-Edwards K. Brain response to injury and neurodegeneration: endogenous neuroprotective signaling. Ann N Y Acad Sci. 2005;1053:137-47.
19. Adams-Graves P, Kedar A, Koshy M, Steinberg M, Veith R, Ward D, et al. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood. 1997;90(5): 2041-6. Epub 1997/09/18.
20. Colbassani HJ, Barrow DL, Sweeney KM, Bakay RA, Check IJ, Hunter RL. Modification of acute focal ischemia in rabbits by poloxamer 188. Stroke; a journal of cerebral circulation. 1989;20(9): 1241-6. Epub 1989/09/01.
21. Smith CM, 2nd, Hebbel RP, Tukey DP, Clawson CC, White JG, Vercellotti GM. Pluronic F-68 reduces the endothelial adherence and improves the rheology of liganded sickle erythrocytes. Blood. 1987;69(6):1631-6. Epub 1987/06/01.
22. Frim DM, Wright DA, Curry DJ, Cromie W, Lee R, Kang UJ. The surfactant poloxamer-188 protects against glutamate toxicity in the rat brain. Neuroreport. 2004;15(1):171-4. Epub 2004/04/27.
23. Yuhua S, Ligen L, Jiake C, Tongzhu S. Effect of Poloxamer 188 on deepening of deep second-degree burn wounds in the early stage. Burns: journal of the International Society for Burn Injuries. 2012; 38(1):95-101. Epub 2011/11/15.
24. Natoli RM, Athanasiou KA. P188 reduces cell death and IGF-I reduces GAG release following single-impact loading of articular cartilage. Journal of biomechanical engineering. 2008;130(4): 041012. Epub 2008/07/08.
25. Phillips DM, Haut RC. The use of a non-ionic surfactant (P188) to save chondrocytes from necrosis following impact loading of chondral explants. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2004;22(5):1135-42. Epub 2004/08/12.
26. Lee RC, River LP, Pan FS, Ji L, Wollmann RL. Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo. Proc Natl Acad Sci U S A. 1992;89(10):4524-8. Epub 1992/05/15.
27. Maskarinec SA, Hannig J, Lee RC, Lee KY. Direct observation of poloxamer 188 insertion into lipid monolayers. Biophysical journal. 2002;82(3):1453-9. Epub 2002/02/28.
28. Lee, RC. Methods and Compositions of a Polymer (Poloxamer) for Repair of Electrical Injury. 5605687, 1997.
29. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol. 1998;16(9):867-70.
30. Trollet C, Bloquel C, Scherman D, Bigey P. Electrotransfer into skeletal muscle for protein expression. Curr Gene Ther. 2006;6(5): 561-78.
31. DiFranco M, Neco P, Capote J, Meera P, Vergara JL. Quantitative evaluation of mammalian skeletal muscle as a heterologous protein expression system. Protein Expr Purif. 2006;47(1):281-8.
32. Lee RC, Kolodney MS. Electrical injury mechanisms: electrical breakdown of cell membranes. Plast Reconstr Surg. 1987;80(5): 672-9.
33. DiVincenti FC, Moncrief JA, Pruitt BA, Jr. Electrical injuries: a review of 65 cases. J Trauma. 1969;9(6):497-507.
34. Tropea BI, Lee RC. Thermal injury kinetics in electrical trauma. Journal of biomechanical engineering. 1992;114(2):241-50.
35. Lee RC, Kolodney MS. Electrical injury mechanisms: dynamics of the thermal response. Plast Reconstr Surg. 1987;80(5):663-71.
36. Lee RC, Zhang D, Hannig J. Biophysical injury mechanisms in electrical shock trauma. Annu Rev Biomed Eng. 2000;2:477-509.
37. Follis F, Jenson B, Blisard K, Hall E, Wong R, Kessler R, et al. Role of poloxamer 188 during recovery from ischemic spinal cord injury: a preliminary study. J Invest Surg. 1996;9(2):149-56.
38. Borgens RB, Bohnert D, Duerstock B, Spomar D, Lee RC. Subcutaneous tri-block copolymer produces recovery from spinal cord injury. J Neurosci Res. 2004;76(1):141-54.
39. Greenebaum B, Blossfield K, Hannig J, Carrillo CS, Beckett MA, Weichselbaum RR, et al. Poloxamer 188 prevents acute necrosis of adult skeletal muscle cells following high-dose irradiation. Burns: journal of the International Society for Burn Injuries. 2004;30(6): 539-47.
40. Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature. 2005;436(7053):1025-9.
41. Quinlan JG, Wong BL, Niemeier RT, McCullough AS, Levin L, Emanuele M. Poloxamer 188 failed to prevent exercise-induced membrane breakdown in mdx skeletal muscle fibers. Neuromuscul Disord. 2006;16(12):855-64.
42. Steinhardt RA, Alderton JM. Poloxamer 188 enhances endothelial cell survival in bovine corneas in cold storage. Cornea. 2006;25(7): 839-44.
43. Kilinc D, Gallo G, Barbee K. Poloxamer 188 reduces axonal beading following mechanical trauma to cultured neurons. Conf Proc IEEE Eng Med Biol Soc. 2007;2007:5395-8.
44. Ng R, Metzger JM, Claflin DR, Faulkner JA. Poloxamer 188 reduces the contraction-induced force decline in lumbrical muscles from mdx mice. Am J Physiol Cell Physiol. 2008;295(1):C146-50.
45. Murphy AD, McCormack MC, Bichara DA, Nguyen JT, Randolph MA, Watkins MT, et al. Poloxamer 188 protects against ischemiareperfusion injury in a murine hind-limb model. Plast Reconstr Surg. 2010;125(6):1651-60.
46. Plataki M, Lee YD, Rasmussen DL, Hubmayr RD. Poloxamer 188 facilitates the repair of alveolus resident cells in ventilator-injured lungs. Am J Respir Crit Care Med. 2011;184(8):939-47. Epub 2011/07/23.
47. Spurney CF, Guerron AD, Yu Q, Sali A, van der Meulen JH, Hoffman EP, et al. Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC Cardiovasc Disord. 2011;11:20.
48. Townsend D, Turner I, Yasuda S, Martindale J, Davis J, Shillingford M, et al. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest. 2010;120(4):1140-50.
49. Lee, RC. Methods and Compositions for Treatment of Free Radical Injury. US2006/0121016 A1, 2006.
50. Hannig J, Zhang D, Canaday DJ, Beckett MA, Astumian RD, Weichselbaum RR, et al. Surfactant sealing of membranes permeabilized by ionizing radiation. Radiation research. 2000;154(2): 171-7. Epub 2000/08/10.
51. Metzger, JM, Townsend, D, Yasuda, S, Michele, DE. Compositions and Methods for Treating and Preventing Cardiomyopathy and Heart Disease. US2008/0260681 A1, 2008.
52. Fong PY, Turner PR, Denetclaw WF, Steinhardt RA. Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. Science. 1990;250(4981):673-6.
53. Deconinck N, Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol. 2007;36(1):1-7.
54. Pasternak C, Wong S, Elson EL. Mechanical function of dystrophin in muscle cells. J Cell Biol. 1995;128(3):355-61.
55. Clemens PR, Kochanek S, Sunada Y, Chan S, Chen HH, Campbell KP, et al. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene therapy. 1996; 3(11):965-72. Epub 1996/11/01.
56. Watchko J, O'Day T, Wang B, Zhou L, Tang Y, Li J, et al. Adenoassociated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Human gene therapy. 2002;13(12):1451-60. Epub 2002/09/07.
57. Yanagihara I, Inui K, Dickson G, Turner G, Piper T, Kaneda Y, et al. Expression of full-length human dystrophin cDNA in mdx mouse muscle by HVJ-liposome injection. Gene therapy. 1996; 3(6): 549-53. Epub 1996/06/01.
58. Gussoni E, Pavlath GK, Lanctot AM, Sharma KR, Miller RG, Steinman L, et al. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature. 1992;356(6368):435-8. Epub 1992/04/02.
59. Gussoni E, Soneoka Y, Strickland CD, Buzney EA, Khan MK, Flint AF, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature. 1999;401(6751):390-4. Epub 1999/10/12.
60. Singh-Joy SD, McLain VC. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. International journal of toxicology. 2008;27 Suppl 2:93-128. Epub 2008/10/10.
61. Grindel JM, Jaworski T, Emanuele RM, Culbreth P. Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog and man. Biopharmaceutics & drug disposition. 2002;23(3):87-103. Epub 2002/08/14.
62. Jewell RC, Khor SP, Kisor DF, LaCroix KA, Wargin WA. Pharmacokinetics of RheothRx injection in healthy male volunteers. Journal of pharmaceutical sciences. 1997;86(7):808-12. Epub 1997/07/01.
63. Tremper KK, Friedman AE, Levine EM, Lapin R, Camarillo D. The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA. The New England journal of medicine. 1982;307(5):277-83. Epub 1982/07/29.
64. Tremper KK, Vercellotti GM, Hammerschmidt DE. Hemodynamic profile of adverse clinical reactions to Fluosol-DA 20%. Critical care medicine. 1984;12(5):428-31. Epub 1984/05/01.
65. Waxman K, Cheung CK, Mason GR. Hypotensive reaction after infusion of a perfluorochemical emulsion. Critical care medicine. 1984;12(7):609-10. Epub 1984/07/01.
66. Vercellotti GM, Hammerschmidt DE. Immunological biocompatibility in blood substitutes. International anesthesiology clinics. 1985;23(1):47-62. Epub 1985/01/01.
67. Vercellotti GM, Hammerschmidt DE, Craddock PR, Jacob HS. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroids prophylaxis. Blood. 1982;59(6):1299-304. Epub 1982/06/01.
68. Markham, BE. Treatment of Chronic Progressive Heart Failure. US2009/0246162 A1, 2009.
69. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85-151.
70. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011;123(4): e18-e209.
71. Austen, WG. Cell Transplantation. US2010/0104542 A1, 2010.
72. Kayed, R. Compositions and Methods Related to Poloxamer Membrane Sealant. US2010/0316590 A1, 2010.
73. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annual review of neuroscience. 2003;26:267-98. Epub 2003/04/22.
74. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein and peptide letters. 2004;11(3):213-28. Epub 2004/06/09.
75. Glabe CG. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiology of aging. 2006;27(4): 570-5. Epub 2006/02/17.
76. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. The Journal of biological chemistry. 2004; 279(45): 46363-6. Epub 2004/09/24.
77. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. The Journal of biological chemistry. 2005;280(17):17294-300. Epub 2005/02/22.
78. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 2001;40(26):7812-9. Epub 2001/06/27.
79. Green JD, Kreplak L, Goldsbury C, Li Blatter X, Stolz M, Cooper GS, et al. Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide. Journal of molecular biology. 2004;342(3):877-87. Epub 2004/09/03.
80. Sokolov Y, Kozak JA, Kayed R, Chanturiya A, Glabe C, Hall JE. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. The Journal of general physiology. 2006;128(6):637-47. Epub 2006/11/15.
81. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416(6880):507-11. Epub 2002/04/05.
82. Kawahara M, Kuroda Y, Arispe N, Rojas E. Alzheimer's betaamyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. The Journal of biological chemistry. 2000;275(19):14077-83. Epub 2000/05/09.
83. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430(7000):631-9. Epub 2004/08/06.
84. Hunter, RH, Emanuele, M. Polymer Therapy for the Treatment of Chronic Microvascular Diseases. US2011/0212047 A1, 2011.
85. Schmidt S, Saunders AM, De La Paz MA, Postel EA, Heinis RM, Agarwal A, et al. Association of the apolipoprotein E gene with age-related macular degeneration: possible effect modification by family history, age, and gender. Molecular vision. 2000;6:287-93. Epub 2001/01/06.
86. Ng, R, Metzger, JM, Reeve, L, Markham, B. Compositions and Methods for Treating and Preventing Skeletal Muscle Deficiencies. US2011/0033412 A1, 2011.
87. Hoffman EP, Brown RH, Jr., Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919-28. Epub 1987/12/24.
88. Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circulation research. 2004;94(8):1023-31. Epub 2004/05/01.
89. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosomelinked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A. 1984;81(4):1189-92. Epub 1984/02/01.
90. Li S, Kimura E, Ng R, Fall BM, Meuse L, Reyes M, et al. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Human molecular genetics. 2006;15(10):1610-22. Epub 2006/04/06.
91. Yeung EW, Whitehead NP, Suchyna TM, Gottlieb PA, Sachs F, Allen DG. Effects of stretch-activated channel blockers on [Ca2+]i and muscle damage in the mdx mouse. The Journal of physiology. 2005;562(Pt 2):367-80. Epub 2004/11/06.
92. Vandebrouck C, Martin D, Colson-Van Schoor M, Debaix H, Gailly P. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. J Cell Biol. 2002;158(6):1089-96. Epub 2002/09/18.
93. Verburg E, Murphy RM, Stephenson DG, Lamb GD. Disruption of excitation-contraction coupling and titin by endogenous Ca2+-activated proteases in toad muscle fibres. The Journal of physiology. 2005;564(Pt 3):775-90. Epub 2005/03/05.